Literature DB >> 7488814

Adult height in women with early-treated congenital adrenal hyperplasia (21-hydroxylase type): relation to body mass index in earlier childhood.

A C Yu1, D B Grant.   

Abstract

To investigate if obesity, as judged by increased body mass index (BMI), during childhood is associated with impaired adult stature in patients with 21-hydroxylase-type congenital adrenal hyperplasia (CAH), a retrospective analysis was carried out on outpatient records of 30 girls with CAH who had reached adult height. Height SD score for age (HtSDS(ca)), HtSDS for bone age (HtSDS(ba)), BMI and steroid dosage in early childhood (3.2-4.6 years) and later childhood (7.2-9.1 years), were compared with adult HtSDS (HtSDS(adlt)), adult HtSDS less mid-parental HtSDS (HtSDS(adlt)-HtSDS(mp)), predicted adult height SDS (HtSDS(pdct)), adult height SDS less predicted adult HtSDS (HtSDS(adlt)-HtSDS(pdct)) and age at menarche. Mean (SD) for HtSDS(adlt) was -1.13 (1.05), mean HtSDS(pdct) -0.12 (0.9) and mean age at menarche 13.5 (1.9) years. BMI in childhood was not correlated with HtSDS(adlt) but showed negative correlations with HtSDS(adlt)-HtSDS(mp) (r = -0.43; p < 0.02) and HtSDS(adlt)-HtSDS(pdct) (r-0.45; p < 0.02). BMI in later childhood showed negative correlations with HtSDS(adlt)-HtSDS(pdct) (r = -0.61; p < 0.001) and age at menarche (r = -0.63; p < 0.001). We conclude that in girls with early-treated CAH, a high BMI during early childhood is associated with loss of genetic height potential, and in later childhood with over-prediction of adult height and early menarche.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7488814     DOI: 10.1111/j.1651-2227.1995.tb13789.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  7 in total

Review 1.  Growth in congenital adrenal hyperplasia.

Authors:  An Tt Nguyen; Justin J Brown; Garry L Warne
Journal:  Indian J Pediatr       Date:  2006-01       Impact factor: 1.967

2.  Final adult height in children with congenital adrenal hyperplasia treated with growth hormone.

Authors:  Karen Lin-Su; Madeleine D Harbison; Oksana Lekarev; Maria G Vogiatzi; Maria I New
Journal:  J Clin Endocrinol Metab       Date:  2011-03-30       Impact factor: 5.958

3.  Bioelectrical impedance analysis of body fatness in childhood congenital adrenal hyperplasia and its metabolic correlates.

Authors:  Pinar Isguven; Ilknur Arslanoglu; Nilgun Mesutoglu; Metin Yildiz; Muferret Erguven
Journal:  Eur J Pediatr       Date:  2008-01-17       Impact factor: 3.183

4.  Growth and reproductive outcomes in congenital adrenal hyperplasia.

Authors:  Todd D Nebesio; Erica A Eugster
Journal:  Int J Pediatr Endocrinol       Date:  2010-02-01

5.  Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients.

Authors:  H J Van der Kamp; B J Otten; N Buitenweg; S M P F De Muinck Keizer-Schrama; W Oostdijk; M Jansen; H A Delemarre-de Waal; T Vulsma; J M Wit
Journal:  Arch Dis Child       Date:  2002-08       Impact factor: 3.791

6.  Obesity in 21-hydroxylase deficient patients.

Authors:  R E Cornean; P C Hindmarsh; C G Brook
Journal:  Arch Dis Child       Date:  1998-03       Impact factor: 3.791

Review 7.  Adrenal hyperplasias in childhood: An update.

Authors:  Georgia Pitsava; Constantine A Stratakis
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-03       Impact factor: 6.055

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.